Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N L Fox

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Arthritis & Rheumatology (Hoboken, N.J.)|April 20, 2018
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus ErythematosusA Doria, W Stohl, A Schwarting, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of Thrombosis and Thrombolysis|June 15, 2001
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatmentJ M Walenga, D Hoppensteadt, R Pifarré, et al.
British Journal of Cancer|November 18, 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes, J M Vose, A D Zelenetz, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
European Heart Journal|December 1, 2001
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PAF Van de Werf, H V Barron, P W Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaT Ciuleanu, I Bazin, D Lungulescu, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Arthritis & Rheumatology (Hoboken, N.J.)|April 20, 2018
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus ErythematosusA Doria, W Stohl, A Schwarting, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of Thrombosis and Thrombolysis|June 15, 2001
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatmentJ M Walenga, D Hoppensteadt, R Pifarré, et al.
British Journal of Cancer|November 18, 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes, J M Vose, A D Zelenetz, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
European Heart Journal|December 1, 2001
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PAF Van de Werf, H V Barron, P W Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaT Ciuleanu, I Bazin, D Lungulescu, et al.
Pageof 4